Abstract: Objective To explore the clinical efficacy and safety of verapamil hydrochloride combined with prednisone in the preventive treatment of cluster headache. Methods A total of 43 patients with cluster headache in Shenyang Red Cross Hospital from March 2020 to March 2021 were randomly divided into an observation group (22 cases) and a control group (21 cases) with the random number table method. There were 17 males and 5 females in the observation group, aged (42.26±12.75) years; there were 14 males and 7 females in the control group, aged (39.26±11.38) years. The observation group was treated with verapamil combined with prednisone, while the control group was treated with verapamil. After two weeks of treatment, the durations of cluster period, headache frequencies, and adverse reactions of the two groups were recorded. Independent sample t test was used for inter-group comparison of measurement data, paired t test was used for intra-group comparison of measurement data, and χ2 test was used for count data. Results Compared with that before the treatment, the pain degree of patients in the observation group and the control group relieved after the treatment, with the total effective rate of 90.91% (20/22) in the observation group and 61.90% (11/21) in the control group, with a statistically significant difference between the two groups (P<0.05). Compared with those before the treatment, the frequencies of headache attack and the durations of cluster period in the two groups decreased after the treatment, and the differences of the two groups before and after the treatment were statistically significant (all P<0.05), and there were statistically significant differences between the observation group and the control group after the treatment (both P<0.05). No serious adverse reactions occurred in both groups during the treatment. Conclusions Verapamil combined with prednisone can prevent cluster headache, and can obviously reduce the duration of cluster period and the frequency of pain attack, and improve the clinical symptoms. Meanwhile, it has good safety and better effect than verapamil alone.

Key words: Cluster headache, Verapamil, Prednisone

摘要： 目的 探讨盐酸维拉帕米联合泼尼松预防性治疗丛集性头痛的临床疗效和安全性。方法 采用随机数字表法将 2020年3月至 2021年3月沈阳市红十字会医院43例丛集性头痛患者分成观察组22例和对照组21例。观察组男17例，女 5例，年龄（42.26±12.75）岁；对照组男14例，女7例，年龄（39.26±11.38）岁。观察组选用维拉帕米联合泼尼松进行治疗，对照组采用维拉帕米进行治疗， 治疗两周后记录两组患者丛集期持续时间、头痛发作频率和不良反应情况等。计量资料组间比较采用独立样本 t 检验，组内比较采用配对 t 检验，计数资料采用 χ2 检验。结果 与治疗前相比，观察组和对照组患者疼痛程度均得到缓解，观察组总有效率 90.91%（20/22），对照组总有效率为 61.90% （11/21），两组相比较差异有统计学意义（P<0.05）。与治疗前相比较，两组患者头痛发作频率和丛集期持续时间均有下降，两组治疗前后相比较差异均有统计学意义（均P<0.05），治疗后观察组与对照组相比较差异均有统计学意义（均 P<0.05）。两组患者在治疗过程中均未发生严重的不良反应。结论 维拉帕米联合泼尼松能够预防性治疗丛集性头痛，并且能够明显降低丛集期持续时间及疼痛发作频率，改善患者临床症状，同时安全性良好，效果优于单独使用维拉帕米。

关键词: 丛集性头痛, 维拉帕米, 泼尼松